This site is intended for health professionals only

Oral calcitonin study initiated

teaser

US- and Swiss-based biopharmaceutical company Unigene Laboratories has initiated a phase I/II clinical study in the USA with its proprietary formulation of oral calcitonin for the treatment of osteoporosis.

Twenty-four healthy postmenopausal women have been enrolled in the study, which will measure the effect of the drug on a well-established biochemical marker.

The dosing is scheduled to be completed by the end of February.

Article continues below this sponsored advert
Featured Image
Explore the latest advances in cardiovascular care delivered by renowned experts from recognised Centres of Excellence and other NHS trusts around the UK. Gain CPD, put your burning questions to the experts, and boost your confidence when it comes to care for your patients.
Advertisement

Executive vice-president Dr Ronald Levy said the tablets being tested in the study utilised the same improved solid dosage form of Unigene’s Enteripep® oral delivery technology, used in Unigene’s prior oral calcitonin study completed last autumn.

In that study, the new dosage form achieved a biological response in 100% of the study subjects.

Unigene






Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine

x